Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.

× No keyword cloud information.

19 in total

1. A tissue-culture approach to demyelinative disorders.

Authors: M B BORNSTEIN
Journal: Natl Cancer Inst Monogr Date: 1963-03

2. Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis.

Authors: T P Seland; T A Mc Pherson; M Grace; G Lamoureux; J G Blain
Journal: Neurology Date: 1974-01 Impact factor: 9.910

Review 3. The selective action of antilymphocyte serum on recirculating lymphocytes: a review of the evidence and alternatives.

Authors: E M Lance
Journal: Clin Exp Immunol Date: 1970-06 Impact factor: 4.330

4. Intensive immunosuppression in the treatment of multiple sclerosis.

Authors: J Ring; J Seifert; G Lob; K Coulin; H Angstwurm; E Frick; B Brass; J Mertin; H Backmund; W Brendel
Journal: Lancet Date: 1974-11-09 Impact factor: 79.321

5. Effect of 'maximum immune suppression' with thoracic duct drainage, ALG, azathioprine and cortisone in some neurological disorders.

Authors: W Brendel; J Seifert; G Lob
Journal: Proc R Soc Med Date: 1972-06

6. Immunological tolerance induced in adult dogs by small amounts of horse IgG.

Authors: W Land; J Seifert; A Fateh-Moghadam; U Hopf; W Brendel
Journal: Transplantation Date: 1969-11 Impact factor: 4.939

7. In vitro delayed (cellular) hypersensitivity in multiple sclerosis to central nervous system antigens.

Authors: H Bartfeld; T Atoynatan
Journal: Int Arch Allergy Appl Immunol Date: 1970

8. Intensive immunosuppression in patients with disseminated sclerosis. II. Tolerance to equine IgG and effect on immunoglobulin and complement levels.

Authors: V E Jones; E M Lance; J Abbosh; H E Graves
Journal: Clin Exp Immunol Date: 1975-07 Impact factor: 4.330

9. Intensive immunosuppression in patients with disseminated sclerosis. III. Lymphocyte response in vitro.

Authors: S C Knight; E M Lance; J Abbosh; A Munro; J O'Brien
Journal: Clin Exp Immunol Date: 1975-07 Impact factor: 4.330

10. The use of specific "lymphocyte" antisera to inhibit hypersensitive reactions of the "delayed" type.

Authors: B H WAKSMAN; S ARBOUYS; B G ARNASON
Journal: J Exp Med Date: 1961-12-01 Impact factor: 14.307

10 in total

Review 1. The evidence justifying immunosuppression therapy in multiple sclerosis.

Authors: J Mertin
Journal: Proc R Soc Med Date: 1977-12

2. Relapse of multiple sclerosis following acute allergic reactions to plasma during plasmapheresis.

Authors: I Wirguin; E Shinar; O Abramsky
Journal: J Neurol Date: 1989-01 Impact factor: 4.849

3. Prolonged azathioprine treatment of non-remitting multiple sclerosis.

Authors: J A Rosen
Journal: J Neurol Neurosurg Psychiatry Date: 1979-04 Impact factor: 10.154

4. Failure of basic protein therapy for multiple sclerosis.

Authors: R E Gonsette; P Delmotte; L Demonty
Journal: J Neurol Date: 1977-08-18 Impact factor: 4.849

5. [Long-term therapy using horse anti-dog lymphocyte globulin without sensitization against horse protein].

Authors: J Scheel; K H Duswald; J Ring; J Seifert; S Scholz; W Brendel
Journal: Blut Date: 1977-04

6. Intensive immunosuppression in patients with disseminated sclerosis. II. Tolerance to equine IgG and effect on immunoglobulin and complement levels.